Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Calcitonin gene-related peptide (CGRP) is a 37-amino acid neuropeptide derived from the alternative processing of mRNA from the calcitonin gene. It is widely distributed in the brain, gut, perivascular nerves, and other tissues. CGRP acts as a potent endogenous vasodilator and plays significant roles in circulatory regulation and neurotransmission. It has been implicated in migraine pathophysiology due to its ability to cause vasodilation, mast cell degranulation, and plasma extravasation when released by sensory neurons during migraine attacks. Elevated levels of CGRP are observed during migraines and other conditions such as cardiac failure and hypertension. As a drug candidate (not an approved pharmaceutical), exogenous CGRP has demonstrated bronchodilatory, bronchoprotective, anti-inflammatory properties in preclinical studies[7][6][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calcitonin gene-related peptide.